Ahmad Hassan Ali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1702814/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Primary biliary cirrhosis. Lancet, The, 2015, 386, 1565-1575.	6.3	502
2	Recent advances in the development of farnesoid X receptor agonists. Annals of Translational Medicine, 2015, 3, 5.	0.7	115
3	Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. Journal of Gastrointestinal Oncology, 2018, 9, 1054-1062.	0.6	110
4	Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. Hepatology, 2018, 67, 2338-2351.	3.6	92
5	Varices in Early Histological Stage Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology, 2011, 45, e66-e71.	1.1	40
6	Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation. Hepatology, 2021, 74, 281-295.	3.6	40
7	Obeticholic acid for the treatment of primary biliary cholangitis. Expert Opinion on Pharmacotherapy, 2016, 17, 1809-1815.	0.9	39
8	Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2022, 23, 7280.	1.8	38
9	Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology, 2020, 55, 941-950.	0.6	31
10	Current research on the treatment of primary sclerosing cholangitis. Intractable and Rare Diseases Research, 2015, 4, 1-6.	0.3	26
11	Diagnosis and management of primary biliary cirrhosis. Expert Review of Clinical Immunology, 2014, 10, 1667-1678.	1.3	20
12	The Microbiome and Primary Sclerosing Cholangitis. Seminars in Liver Disease, 2016, 36, 340-348.	1.8	15
13	Single-cell mass cytometry on peripheral blood identifies immune cell subsets associated with primary biliary cholangitis. Scientific Reports, 2020, 10, 12584.	1.6	13
14	The management of autoimmunity in patients with cholestatic liver diseases. Expert Review of Gastroenterology and Hepatology, 2016, 10, 73-91.	1.4	12
15	The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience. Journal of Gastroenterology, 2020, 55, 1087-1097.	2.3	10
16	Successful response of primary sclerosing cholangitis and associated ulcerative colitis to oral vancomycin may depend on brand and personalized dose: report in an adolescent. Clinical Journal of Gastroenterology, 2021, 14, 684-689.	0.4	8
17	The Utility and Diagnostic Accuracy of Transient Elastography in Adults with Morbid Obesity: A Prospective Study. Journal of Clinical Medicine, 2022, 11, 1201.	1.0	8
18	Clinically Actionable Findings Derived From Predictive Genomic Testing Offered in a Medical Practice Setting. Mayo Clinic Proceedings, 2021, 96, 1407-1417.	1.4	6

AHMAD HASSAN ALI

#	Article	IF	CITATIONS
19	Potential Association of Doxycycline With the Onset of Primary Sclerosing Cholangitis: A Case Series. American Journal of Therapeutics, 2022, 29, e437-e443.	0.5	5
20	A Model Incorporating Serum Alkaline Phosphatase for Prediction of Liver Fibrosis in Adults with Obesity and Nonalcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2021, 10, 3311.	1.0	4
21	Evaluation of circulating cell-free DNA in cholestatic liver disease using liver-specific methylation markers. BMC Gastroenterology, 2021, 21, 149.	0.8	3
22	An overview of current and future therapeutic strategies for the treatment of primary sclerosing cholangitis. Expert Opinion on Orphan Drugs, 2014, 2, 545-556.	0.5	1
23	The PSC scientific community resource: an asset for multi-omics interrogation of primary sclerosing cholangitis. BMC Gastroenterology, 2021, 21, 353.	0.8	1
24	Targets and investigative treatments for primary biliary cholangitis. Expert Opinion on Orphan Drugs, 2016, 4, 1011-1020.	0.5	0
25	Associations Between Drug Exposure and Outcomes in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 1244-1245.	2.4	0
26	Cholangiocarcinoma Surveillance in Primary Sclerosing Cholangitis and IgG4-Related Sclerosing Cholangitis. , 2021, , 435-448.		0